[ad_1]
An FDA-approved drug currently used to treat multiple sclerosis has been shown to be effective for pancreatic cancer. Researchers from the Rajiv Gandhi Center for Biotechnology (RGCB), Thiruvananthapuram, in collaboration with the Regional Cancer Center of the city and NIMHANS, Bengaluru, discovered that the drug was also able to increase the effectiveness of the Gemcitabine, the current standard drug for pancreatic cancer. The results of the study were published recently in Theranostics
The drug used to treat multiple sclerosis acts through a receptor called S1PR1 involved in lipid signaling and regulating many cellular events such as the cell growth. , migration and vascular integrity.
"The precise role of the receptor in pancreatic cancer is still unclear, and our study has shown that it is important, and we found that the drug of multiple sclerosis [multiple] can bind to receptor and modify key cellular events and prevent the progression of pancreatic cancer, "says Dr. KB Harikumar, of the RGCB Cancer Research Program and corresponding author of the document .The drug against sclerosis turned out to be a potent inhibitor of NF-kappaB, a transcription factor that aids tumor progression
The efficacy of the multiple sclerosis drug was tested in mice The combined drug therapy was able to control a variety of signaling molecules, thereby decreasing the proliferation of cancer cells and increasing apoptosis.He also helped to produce higher levels Reactive species of oxygen and inhibited the migration of cancer cells. They also studied the genes involved in inflammation and immunity in pancreatic cancer and found that the drug regimen activated a tumor suppressor gene and down-regulated another involved in drug resistance and resistance. decreased immunity
also addressed one of the major problems in pancreatic cancer known as desmoplasia, which is the presence of a collagen-rich deposit around the tumor. Collagen deposition leads to poor clinical outcome due to a decrease in drug delivery to the tumor. "In fact, gemcitabine itself leads to desmoplasia, which reduces its own effect.We have found that the drug combination reduces desmoplasia.Sclerotic Sclerosis [multiple] relieves the tumor and helps gemcitabine to enter the tumor, thus increasing the bioavailability of the anticancer drug, "adds Dr. Harikumar
suggesting the promising possibility of using it for the treatment of pancreatic cancer.
" The reuse of existing drugs reduces the time required to put the drugs on clinical trial.In addition, the use of combination drugs can reduce the dosage of drugs, thereby reducing the side effects, "says Manendra Babu Lankadasari, researcher at the Center and first author from the study in an email to The Hindu
[ad_2]
Source link
